ARK Invest Exits Meta (META) and Roku (ROKU) Positions While Boosting Tempus AI Stake

Key Takeaways

• ARK Invest liquidated 3,578 Meta (META) shares valued at approximately $2.1 million from three separate funds
• The firm offloaded 95,090 Roku (ROKU) shares worth roughly $9.1 million across several ETFs
• ARK purchased 84,939 Tempus AI shares totaling approximately $4.1 million during Wednesday’s session
• Tempus AI now represents the third-largest position in ARK Innovation ETF at approximately 5% portfolio weight
• Meta faced a social media addiction lawsuit verdict and announced workforce reductions affecting hundreds of employees

Cathie Wood’s ARK Invest reduced its exposure to Meta and Roku on Wednesday, March 25, redirecting capital toward healthcare artificial intelligence firm Tempus AI.

Meta Platforms, Inc., META

The investment firm divested 3,578 shares of Meta spread across three separate funds. Calculated using Wednesday’s closing price, the transaction totaled approximately $2.1 million. Following this sale, ARK Innovation ETF maintains a position of roughly 105,000 Meta shares valued at nearly $63 million — representing about 1% of the portfolio.

Wednesday proved eventful for Meta on multiple fronts. A jury delivered a verdict determining that both the company and Google’s YouTube demonstrated negligence by operating platforms that caused harm to minors in a groundbreaking social media addiction case. Both tech giants indicated their intention to challenge the ruling.

Meta simultaneously introduced a revised executive compensation structure designed to incentivize a 500% stock price surge and achieve a $9 trillion market capitalization by 2031. The social media giant acknowledged to Barron’s that it was eliminating several hundred positions spanning sales, recruitment, and virtual reality departments. Nonetheless, Meta stock closed Wednesday’s trading session with a modest 0.3% gain.

ARK simultaneously liquidated 95,090 Roku shares distributed across its ARKK, ARKW, and ARKF portfolios, generating approximately $9.1 million. This transaction continues a selling pattern established the previous trading day on March 24.

Supplementary divestments included 30,174 Teradyne shares valued at roughly $9.7 million, along with 205,019 Bullish shares across three ETFs totaling about $7.7 million. The firm has maintained a consistent selling pattern with Bullish throughout the previous week.

Further sales encompassed 62,393 Kratos Defense shares and 27,647 Natera shares, generating $4.8 million and $5.4 million respectively.

Tempus AI Emerges as ARK’s Preferred Investment

Regarding purchases, ARK’s primary transaction focused on Tempus AI. The investment firm acquired 84,939 shares through its ARKK and ARKG portfolios, deploying approximately $4.1 million.

Tempus AI declined 4.2% during Wednesday’s session and has retreated 21% year-to-date in 2026. ARK’s acquisition appears to capitalize on the price weakness.

ARK Innovation ETF currently maintains approximately 6.3 million Tempus AI shares valued above $294 million. This position now ranks as the portfolio’s third-largest allocation, trailing only Tesla and Crispr Therapeutics, comprising roughly 5% of total fund assets.

Strategic Portfolio Rebalancing Continues

ARK’s Wednesday transactions reflect an ongoing strategic shift. The firm has systematically decreased allocations in Roku, Teradyne, and Bullish across multiple consecutive trading sessions.

Concurrently, it has aggressively expanded its Tempus AI holdings. Tempus AI operates as a healthcare technology enterprise leveraging artificial intelligence to enhance medical data analytics and oncology treatment protocols.

Minor acquisitions during the session also encompassed shares of Archer Aviation, Beam Therapeutics, and additional portfolio companies.

The ARK Innovation ETF finished Wednesday’s trading up 1.3%.